Atrium Therapeutics, Inc.
NASDAQ:RNABiotechnology
+$0.16 today
- Market cap
- $143.23M
- Beta
- 0.42
- P/E (TTM)
- -3.3
- EPS (TTM)
- -$3.78
Volume 0.22M
Average 0.35M
RNA Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Atrium Therapeutics, Inc.NASDAQ: RNA
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables of -$3.59M in Q1 FY2026
Q1 FY2026 accounts payables was -$3.59M.
Context
- Accounts payables amounted to 20.0% of revenue in FY2025.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- 3.73M USD
- Year-over-year change
- —
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.73M | — |
Accounts Payables vs competitors
How RNA compares with its peers on the latest reported figures
No competitor Accounts Payables figures are available to compare.
Cash Flow Statement
Atrium Therapeutics, Inc.
NASDAQ:RNA
Intrinsic Alpha fair value
Locked
Current Price
$6.64
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.